APSR2026-825

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP12-052
P129
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1219919-46904-AP12-052(Tackling The Vicious Viscous Mucous Nebulized Tyloxapol for Airway Clearance in Bronchiectasis)_434099.pdf
Format: PDF Only
16. Interstitial Lung Disease
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Wei Han Hoh * Institut Perubatan Respiratori (IPR) Respiratory Department Kuala Lumpur Malaysia
Syazatul Syakirin Sirol Aflah - Institut Perubatan Respiratori (IPR) Respiratory Department Kuala Lumpur Malaysia
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Wei Han
Hoh
ivanhohwh89@gmail.com
+60122800391
31-40
Malaysia
Case Report
Tackling The Vicious Viscous Mucous: Nebulized Tyloxapol for Airway Clearance in Bronchiectasis.
Maximum 25 words
Abstract Content
 
 
 
 
Airway clearance is the cornerstone of managing bronchiectasis, yet achieving effective results is often challenging in patients with high volume sputum burden with frequent exacerbations. When conventional methods such as oral mucolytics and oscillating positive expiratory pressure (OPEP) are insufficient, we explore the use of nebulised Tyloxapol (Tacholiquin) as an adjunctive therapy. As an inhaled surfactant, it physically reduces sputum surface tension to facilitate easier mobilization of tenacious secretions.
A 63-year-old female with extensive bilateral bronchiectasis and chronic Pseudomonas aeruginosa colonization presented with a high daily sputum burden and respiratory failure which required oxygen support. Her clinical course was further complicated by haemoptysis. Despite a maximal conventional regimen, including oral N-acetylcysteine, immunomodulatory azithromycin, and OPEP therapy (Aerobika), she continued to struggle with thick and retained secretions. To optimize clearance and mitigate exacerbation risks, nebulized Tyloxapol was initiated as a combined treatment. This addition successfully facilitated the mobilization and expectoration of thick copious mucus, safely improving airway hygiene despite her compromised lung mechanics and hypoxemia.
This case highlights the efficacy of nebulized Tyloxapol as an adjunctive strategy in advanced suppurative airway disease. By lowering the surface tension of the mucous layer, Tyloxapol physically breaks the cycle of mucus stasis. In patients where standard mucolytics and mechanical OPEP devices provide incomplete relief, this combined approach offers a safe, non-invasive method to enhance clearance. For fragile patients with high sputum volumes and recurrent infections, optimizing airway clearance with Tyloxapol is a vital intervention to reduce the frequency of life-threatening exacerbations.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Tyloxapol, Bronchiectasis, Airway clearance
maximum 3 keywords and no abbreviations, separated by commas
Nil
247